All Blogs / Industries / Medical / Pharmaceutical / New


Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Hospira, Vertex and Lots More!!

Hello, everyone, and welcome to another working week. We hope those of you on this side of the pond enjoyed the long holiday weekend and had a chance to hit the refresh button, because that familiar routine of meetings, deadlines and what-not has predictably returned. Show More Summary

Cryo-EM On the March

Cryo-electron microscopy has been scoring some real successes lately as a structural biology technique. Anything that provides protein structures without having to crystallize proteins is of immediate interest, of course, and I think we can expect a lot more work in this area. Show More Summary

Celgene Expanding

Readers who have worked in the NJ pharma world will be familiar with the big research campus in Summit. I go back far enough to remember it from my first round of job interviews, when it was still Ciba-Geigy. (I was on my post-doc in Germany at the time, and I'd already been asked if I would consider a job in Basel. Show More Summary

Express Scripts New Trend O’ Drugs Report: Price Without Value (rerun)

I’m taking a break from blogging this week and rerunning some popular posts from early 2015. Click here to see the original post and comments from March 2015. Last week, Express Scripts released its new 2014 Drug Trend Report. Click here to download the complete report. Show More Summary

Novo Nordisk Halts Sale of Tresiba Insulin in Germany Over Pricing Dispute

Novo Nordisk has decided to halt sales of its Tresiba insulin in Germany following a dispute with the National Association of Statutory Health Insurance Funds.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Glaxo, Research Fraud and Lots More!!

And so, another working week will soon draw to a close, at least on this side of the pond, where a holiday is just around the corner. As a result, we are getting an earlier-than-usual opportunity to daydream about weekend plans. Hooray!...Show More Summary

The End Result of Faked Results

Oh, man. Here's another example of an old, sad story - just a little fakery at the beginning, and here's what it leads to: Government prosecutors said (Dong-Pyou) Han's misconduct dates to 2008 when he worked at Case Western ReserveShow More Summary

Alzheimer's Disposes of Another Idea

In case you were wondering, you can add "MAO-B inhibition" to the long, long list of Things That Don't Do Any Good For Alzheimer's. I'm not sure how much hope anyone had for that program (at either Roche or Evotec), but the potential payoff is so huge that a lot of marginal ideas get tried. At least this was in Phase II, and not Phase III; there's always that...

Chris Viehbacher's Two Billion Dollars

Chris Viehbacher, ex-Sanofi, has reappeared at a $2 billion dollar biotech fund. Viehbacher is clear, though, that Gurnet will be founding companies as well as looking outside the red-hot fields like oncology. To find value these days, you have to look outside of the trendiest fields, he says. Show More Summary

Lipids, Proteins, and Chapman's Homer

Longtime readers might recall that every so often I hit on the topic of the "dark matter" of drug target space. We have a lot of agents that hit G-protein coupled receptor proteins, and plenty that inhibit enzymes. Those, though, are...Show More Summary

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Novartis, Taxes and Much More!!

Good morning, everyone, and how are you today? A spot of rain is descending on the Pharmalot campus, but our spirits remain as sunny as ever. As you may recall us noting previously, the Morning Mayor used to say that 'every brand new...Show More Summary

Hotel Workers Want to End Pharma Support of Continuing Medical Ed

A union that represents hotel workers has started a campaign to end pharmaceutical industry funding of continuing medical education.

How Much?! Feds Wants Novartis to pay $3.35B For Kickback Schemes

The U.S. Department of Justice says that Novartis should pay up to $3.35 billion in damages and civil fines for using kickbacks to boost sales of two drugs that caused federal health care programs to overpay for medicines.

Did Celgene Make the Right Move with its Juno Deal? What the Wags Say…

Celgene placed a big bet on a hot therapy that harnesses the immune system to fight cancer, by striking a deal with Juno Therapeutics, but the deal was greeted with a mix of enthusiasm and skepticism.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on AIDS, Roche and Lots More!!

Rise and shine, another busy day is on the way. A long-holiday weekend may be looming on this side of the pond, but we remain as engaged as ever in sorting out a never-ending stream of events. Of course, a few cups of stimulation make the task much easier. Show More Summary

Two Alzheimer's Updates (Lilly and TauRx)

When you look at the stock charts of the major pharma companies, there's not a lot of excitement to be had. Until you get to Eli Lilly, that is. Over the last year, the S&P 500 is up about 5%, and most of the big drug stocks are actually negative (Merck -0.4%, Sanofi down 6%, J&J down 7%, AstraZeneca down 13%). Show More Summary

News Roundup, June 2015: Diplomat, Burman’s, CVS, Target, and the Drugstore Outlook

Summer vacation is here! Before you launch your July 4 festivities, please enjoy these Drug Channels fireworks: The valuation behind Diplomat’s acquisition of Burman’s specialty pharmacy A Wall Street perspective on the CVS-Target deal The outlook for drugstore chains Plus, we revisit a stirring patriotic message from Sam the Eagle. Show More Summary

Copyright © 2015 Regator, LLC